This Phase 1 study is testing engineered NK Cells (a type of immune cell) for people with recurrent glioblastoma (a type of brain tumor). These NK Cells are designed to target specific markers on cancer cells. Researchers want to find the safest and best way to give these NK Cells, either directly into the brain using an Ommaya Reservoir or through an IV (into a vein). The main goal is to see how safe the treatment is and what side effects might occur. You may be able to join if you are 18 or older, have recurrent glioblastoma that has been confirmed by a biopsy, and have already had radiation and temozolomide therapy. This study plans to enroll 36 participants, but its current recruitment status is unclear.

Study design

This is a Phase 1 interventional study planning to enroll 36 participants. It will compare giving engineered NK Cells through three different routes: intra-tumoral, intra-ventricular, or intra-arterial injection.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Safety and side effects will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.